O Brien Greene & Co. Inc Purchases Shares of 60,000 Acurx Pharmaceuticals, Inc. $ACXP

O Brien Greene & Co. Inc purchased a new position in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) in the 2nd quarter, Holdings Channel reports. The firm purchased 60,000 shares of the company’s stock, valued at approximately $31,000.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ACXP. Wall Street Zen lowered Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, October 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $31.00 price target on shares of Acurx Pharmaceuticals in a research report on Tuesday, September 30th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $31.00.

Acurx Pharmaceuticals Stock Down 2.9%

Shares of ACXP opened at $5.00 on Friday. Acurx Pharmaceuticals, Inc. has a 52-week low of $3.80 and a 52-week high of $38.00. The firm has a market cap of $7.90 million, a price-to-earnings ratio of -0.47 and a beta of -1.27. The business’s 50 day moving average is $5.20 and its two-hundred day moving average is $6.91.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.00) by $0.11. On average, equities analysts expect that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current fiscal year.

Acurx Pharmaceuticals Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.